Vol. 4, Issue 4, 2022October 13, 2022 BST
Effectiveness and Safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: 3-Year Follow-up of the Belgian Ibrutinib Real-World Data (BiRD) Study
Effectiveness and Safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: 3-Year Follow-up of the Belgian Ibrutinib Real-World Data (BiRD) Study
Ann Janssens, Zwi N. Berneman, Fritz Offner, Sylvia Snauwaert, Philippe Mineur, Gaetan Vanstraelen, Stef Meers, Isabelle Spoormans, Dominique Bron, Isabelle Vande Broek, Charlotte Van Bogaert, Birgit De Beleyr, Ann Smet, Lasse Nielsen, Robert Wapenaar, Marc André,
Janssens, Ann, Zwi N. Berneman, Fritz Offner, Sylvia Snauwaert, Philippe Mineur, Gaetan Vanstraelen, Stef Meers, et al. 2022. “Effectiveness and Safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: 3-Year Follow-up of the Belgian Ibrutinib Real-World Data (BiRD) Study.” Clinical Hematology International 4 (4): 133–43. https://doi.org/10.1007/s44228-022-00020-8.